Catalyst Pharmaceuticals, Inc. $CPRX Holdings Boosted by Globeflex Capital L P

Globeflex Capital L P increased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 54.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 450,580 shares of the biopharmaceutical company’s stock after buying an additional 158,372 shares during the quarter. Catalyst Pharmaceuticals accounts for 1.7% of Globeflex Capital L P’s portfolio, making the stock its 5th largest position. Globeflex Capital L P’s holdings in Catalyst Pharmaceuticals were worth $11,156,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Smartleaf Asset Management LLC grew its position in Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 630 shares during the last quarter. Clearstead Advisors LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 192.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 1,167 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 552.7% in the 4th quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 1,564 shares during the last quarter. Advisory Services Network LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at $39,000. Finally, Quarry LP purchased a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at $40,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

CPRX has been the topic of a number of analyst reports. Zacks Research cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Stephens set a $32.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Robert W. Baird cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Citigroup downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $35.00 to $31.50 in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $31.49 on Thursday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $32.56. The stock has a market capitalization of $3.86 billion, a price-to-earnings ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74. The company’s 50 day moving average price is $31.37 and its 200-day moving average price is $27.21.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).